Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

DISEASE CHARACTERISTICS:

Histologically confirmed invasive mammary carcinoma

Stage IV disease
Basal-like disease (triple-negative, hormone-refractory, HER2-negative)
No locally recurrent breast cancer

No symptomatic brain metastases

Patients with a history of brain metastases are eligible provided they are clinically stable for > 3 weeks after completion of radiotherapy and are not taking steroids or therapeutic anticonvulsants that are cytochrome P450 3A4 (CYP3A4) modifiers
Patients with asymptomatic brain metastases are eligible provided they are not taking prophylactic anticonvulsants that are CYP3A4 modifiers

PATIENT CHARACTERISTICS:

Pre- or post-menopausal
European Cooperative Oncology Group (ECOG) performance status 0-1
Life expectancy ≥ 6 months
Absolute neutrophil count (ANC) ≥ 1,000/mm^3
Platelet count ≥ 100,000/mm^3
Creatinine ≤ 1.5 times upper limit of normal (ULN)

Total bilirubin ≤ 1.5 times ULN (≤ 3 times ULN in the presence of liver metastasis)

Direct bilirubin will be measured in patients with Gilbert syndrome
serum glutamate oxaloacetate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) ≤ 1.5 times ULN (≤ 3 times ULN in the presence of liver metastasis)
Alkaline phosphatase ≤ 3 times ULN (in the presence of liver metastasis)
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective barrier contraception during and for 3 months after completion of study treatment
Able to swallow and retain oral medication
No malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel

No concurrent uncontrolled illness including, but not limited to, any of the following:

Ongoing or active infection requiring parenteral antibiotics
Impaired lung function (chronic obstructive pulmonary disease or lung conditions requiring oxygen therapy)
New York Heart Association class III-IV congestive heart failure
Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within the past 6 months
Uncontrolled hypertension (systolic BP > 180 mm Hg or diastolic BP > 100 mm Hg, found on 2 consecutive measurements separated by a 1-week period and despite adequate medical support)
Clinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment [grade 3 according to NCI Common Toxicity Criteria for Adverse Events v3.0])
Uncontrolled diabetes (hyperosmolar state, ketoacidosis, etc.)
Psychiatric illness or social situations that would compromise patient safety or limit compliance with study requirements including maintenance of a compliance/pill diary
No symptomatic neuropathy ≥ grade 2
No other invasive cancer within the past 5 years except for completely resected basal cell or squamous cell carcinoma of the skin or successfully treated cervical carcinoma in situ
No hypersensitivity to paclitaxel or drugs using the vehicle Cremophor, Chinese hamster ovary cell products, or other recombinant human antibodies
No history of hepatitis B or C

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
Recovered from prior therapy
Prior total cumulative life-time dose of doxorubicin ≤ 360 mg/m^2 or epirubicin ≤ 640 mg/m^2
No more than 4 prior chemotherapy treatments in the metastatic setting (not including endocrine therapy or single-agent biologic therapy)
At least 2 weeks since prior investigational drugs
At least 14 days since prior and no concurrent herbal or dietary supplements
At least 14 days since prior and no concurrent CYP3A4 inducers
At least 7 days since prior and no concurrent CYP3A4 inhibitors
Concurrent radiotherapy to painful bone metastases or areas of impending bone fracture allowed provided radiotherapy is initiated before study entry
No other concurrent anticancer therapy (chemotherapy, radiotherapy, surgery, immunotherapy, hormonal therapy, biologic therapy)